Genital Herpes Clinical Trial
Official title:
The VIBLOK SAfety and perFormancE Trial
Genital herpes has a high prevalence in industrialized as well as developing countries.
Genital herpes causes genital ulcers, increases risk for acquiring HIV infection, and may be
transmitted mother to child during birth with possible serious consequences.
Medical treatments and condoms only partially reduce the risk for transmission from/ to
sexual partners. Genital herpes transmission despite use of condoms is thought to be due to
transfer via skin-to-skin contact in unprotected areas, and HSV-2 transmission may be
enhanced by current shaving habits in the genital area leading to micro lesions (lacerations)
of the skin.
VIBLOKā¢ is a cream designed to impede the passage of viruses, such as HSV-2, across the skin.
Bench and animal experiments indicate that it can block virus transmission such as HSV-2 over
80%.
The objective of the SAFE trial is to assess the safety and performance of VIBLOK in adults
with HSV-2 infection by comparing virus detection in the extra-genital area before and after
application of the barrier cream.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06033261 -
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
|
Phase 1/Phase 2 | |
Completed |
NCT01132729 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
|
N/A | |
Completed |
NCT00362297 -
Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
|
Phase 4 | |
Completed |
NCT01132716 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
|
N/A | |
Completed |
NCT03831165 -
Melatonin Effects on Genital Herpes in Brazilian Women
|
Phase 4 | |
Terminated |
NCT01658826 -
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
|
Phase 2 | |
Completed |
NCT00262106 -
Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection
|
Phase 3 | |
Completed |
NCT01346475 -
Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
|
Phase 4 | |
Completed |
NCT01390805 -
Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)
|
N/A | |
Terminated |
NCT03146403 -
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
|
Phase 2 | |
Completed |
NCT00306787 -
Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes
|
Phase 3 | |
Completed |
NCT00231049 -
Trial Evaluating Safety, Tolerability and Immune Response of AG-707
|
Phase 1 | |
Completed |
NCT00495573 -
HSV-2 Shedding Resolution After Acyclovir Treatment
|
N/A | |
Completed |
NCT00477334 -
Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients
|
Phase 4 | |
Not yet recruiting |
NCT03595995 -
A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621
|
Phase 2 | |
Completed |
NCT01281007 -
Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes
|
Phase 3 | |
Completed |
NCT01112956 -
Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2
|
N/A | |
Completed |
NCT00129818 -
A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding
|
Phase 4 | |
Completed |
NCT00808405 -
GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women
|
N/A | |
Terminated |
NCT00495716 -
Effect of HSV-2 Suppressive Therapy on Sexual Behavior
|
Phase 4 |